Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen

ABSTRACT

BACKGROUND: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). METHODS: Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID. Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion. Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose. The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy. RESULTS: Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled. Total tofacitinib exposure was 16,291 patient-years. Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points). Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies. The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8. For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality. Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained. CONCLUSIONS: Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA. Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions. TRIAL REGISTRATION: NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006). More... »

PAGES

89

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-019-1866-2

DOI

http://dx.doi.org/10.1186/s13075-019-1866-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113262126

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30953540


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Rheumatologie Hamburg, Struenseehaus, Hamburg, Germany."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wollenhaupt", 
        "givenName": "J\u00fcrgen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seoul National University", 
          "id": "https://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Seoul National University, Seoul, Republic of Korea."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Eun-Bong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alabama at Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "University of Alabama at Birmingham, Birmingham, AL, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curtis", 
        "givenName": "Jeffrey R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Healthpoint Medical Group, Tampa, FL, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silverfield", 
        "givenName": "Joel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Terry", 
        "givenName": "Ketti", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soma", 
        "givenName": "Koshika", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mojcik", 
        "givenName": "Chris", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "DeMasi", 
        "givenName": "Ryan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (Netherlands)", 
          "id": "https://www.grid.ac/institutes/grid.487416.8", 
          "name": [
            "Pfizer Inc, Capelle aan den Ijssel, Netherlands."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strengholt", 
        "givenName": "Sander", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kwok", 
        "givenName": "Kenneth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "IQVIA Canada, Montr\u00e9al, Quebec, Canada."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lazariciu", 
        "givenName": "Irina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA. Lisy.Wang@pfizer.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Lisy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/art.33383", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001564462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002267298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39972", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006385965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39972", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006385965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39972", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006385965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39972", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006385965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-207319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006915863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-016-0932-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008879334", 
          "https://doi.org/10.1186/s13075-016-0932-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1109071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010422264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.38687", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012858308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61424-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013407721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2005.043166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015096737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016554784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2016.11.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018628442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2016.11.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018628442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1310476", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024691370"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.22039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031937720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-209055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034784737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.24567", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035997671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.24567", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035997671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2013-204627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038025398"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2009.118935", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038366856"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-209064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041863543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.37816", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042973954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.130683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043063467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/14397595.2014.995875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049271633"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/14397595.2014.995875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049271633"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.20494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049859067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.33419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050813312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kev249", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060012588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-159-4-201308200-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073713806"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083399754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehx145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084183736"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)31618-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086040585"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/rmdopen-2017-000491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100989117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/rmdopen-2017-000491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100989117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-018-0097-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101169712", 
          "https://doi.org/10.1007/s40744-018-0097-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-018-0097-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101169712", 
          "https://doi.org/10.1007/s40744-018-0097-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-018-0097-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101169712", 
          "https://doi.org/10.1007/s40744-018-0097-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.170344", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103284630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.40580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104327999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.40780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109891225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.40780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109891225"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5\u2009mg and 10\u2009mg twice daily (BID) for up to 9.5\u2009years in patients with rheumatoid arthritis (RA).\nMETHODS: Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5\u2009mg or 10\u2009mg BID. Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion. Assignment to dose groups (5\u2009mg or 10\u2009mg BID) was based on patients' average total daily dose. The primary objective was to determine the long-term safety and tolerability of tofacitinib 5\u2009mg and 10\u2009mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy.\nRESULTS: Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled. Total tofacitinib exposure was 16,291 patient-years. Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5\u2009mg BID and month 72 for 10\u2009mg BID (with low patient numbers limiting interpretation beyond these time points). Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies. The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8. For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality. Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained.\nCONCLUSIONS: Tofacitinib 5\u2009mg and 10\u2009mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA. Safety data are reported up to 9.5\u2009years, and efficacy data up to 8\u2009years, based on adequate patient numbers to support conclusions.\nTRIAL REGISTRATION: NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-019-1866-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.", 
    "pagination": "89", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-019-1866-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113262126"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30953540"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-019-1866-2", 
      "https://app.dimensions.ai/details/publication/pub.1113262126"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1866-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1866-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1866-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1866-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1866-2'


 

This table displays all metadata directly associated to this object as RDF triples.

258 TRIPLES      21 PREDICATES      61 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-019-1866-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4d57aa643afe45c6834a8fea08778ce9
4 schema:citation sg:pub.10.1007/s40744-018-0097-3
5 sg:pub.10.1186/s13075-016-0932-2
6 https://doi.org/10.1002/acr.20494
7 https://doi.org/10.1002/acr.22039
8 https://doi.org/10.1002/art.24567
9 https://doi.org/10.1002/art.33383
10 https://doi.org/10.1002/art.33419
11 https://doi.org/10.1002/art.37816
12 https://doi.org/10.1002/art.38687
13 https://doi.org/10.1002/art.39761
14 https://doi.org/10.1002/art.39972
15 https://doi.org/10.1002/art.40580
16 https://doi.org/10.1002/art.40780
17 https://doi.org/10.1016/j.clinthera.2016.11.004
18 https://doi.org/10.1016/s0140-6736(12)61424-x
19 https://doi.org/10.1016/s0140-6736(17)31618-5
20 https://doi.org/10.1056/nejmoa1109071
21 https://doi.org/10.1056/nejmoa1112072
22 https://doi.org/10.1056/nejmoa1310476
23 https://doi.org/10.1093/eurheartj/ehx145
24 https://doi.org/10.1093/rheumatology/kev249
25 https://doi.org/10.1136/annrheumdis-2013-204627
26 https://doi.org/10.1136/annrheumdis-2015-207319
27 https://doi.org/10.1136/annrheumdis-2015-209055
28 https://doi.org/10.1136/annrheumdis-2015-209064
29 https://doi.org/10.1136/annrheumdis-2016-210457
30 https://doi.org/10.1136/ard.2005.043166
31 https://doi.org/10.1136/ard.2009.118935
32 https://doi.org/10.1136/rmdopen-2017-000491
33 https://doi.org/10.3109/14397595.2014.995875
34 https://doi.org/10.3899/jrheum.130683
35 https://doi.org/10.3899/jrheum.170344
36 https://doi.org/10.7326/0003-4819-159-4-201308200-00006
37 schema:datePublished 2019-12
38 schema:datePublishedReg 2019-12-01
39 schema:description BACKGROUND: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). METHODS: Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID. Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion. Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose. The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy. RESULTS: Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled. Total tofacitinib exposure was 16,291 patient-years. Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points). Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies. The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8. For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality. Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained. CONCLUSIONS: Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA. Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions. TRIAL REGISTRATION: NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N6a9b79c933704891b8bd3b947978bef9
44 Nf346b2667d544047b015ef78ed03415e
45 sg:journal.1297499
46 schema:name Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
47 schema:pagination 89
48 schema:productId N3f95e168e7e649759859f7f9b464f354
49 N46d3f66639b8469a833c3fc10d73ed48
50 Nc35f82bfa1524ac3ac29a04d459cadb0
51 Nf53504ca49cb40e69192b069b145d22a
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113262126
53 https://doi.org/10.1186/s13075-019-1866-2
54 schema:sdDatePublished 2019-04-15T09:01
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N794d5f5a93a041e98698deec6264467d
57 schema:url https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1866-2
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N1fd93f16c5074118bc5e03f7e3f2c9fc schema:affiliation Nf0658dac004e4a9ba2817ae374f52164
62 schema:familyName Lazariciu
63 schema:givenName Irina
64 rdf:type schema:Person
65 N3f95e168e7e649759859f7f9b464f354 schema:name pubmed_id
66 schema:value 30953540
67 rdf:type schema:PropertyValue
68 N46d3f66639b8469a833c3fc10d73ed48 schema:name dimensions_id
69 schema:value pub.1113262126
70 rdf:type schema:PropertyValue
71 N4a8f70030e614f9494960b5c45dfe57b schema:affiliation https://www.grid.ac/institutes/grid.265892.2
72 schema:familyName Curtis
73 schema:givenName Jeffrey R
74 rdf:type schema:Person
75 N4d57aa643afe45c6834a8fea08778ce9 rdf:first N85dc530cb0644714a73c242fbf1ab549
76 rdf:rest Nc94ae35a0e94431c99d5555ee80fd007
77 N5215375658cf44d98b26b4b809120481 schema:name Rheumatologie Hamburg, Struenseehaus, Hamburg, Germany.
78 rdf:type schema:Organization
79 N5290ccccdfc8408a99fc37a1af82567b schema:affiliation https://www.grid.ac/institutes/grid.267313.2
80 schema:familyName Cohen
81 schema:givenName Stanley
82 rdf:type schema:Person
83 N5af97cbf56a143e79eba9593911f91f8 schema:affiliation Necc92a437aca4e05a9e595144fceeafa
84 schema:familyName Silverfield
85 schema:givenName Joel
86 rdf:type schema:Person
87 N64aeb8d93bfb48bf89c6d78ef00b0086 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
88 schema:familyName Terry
89 schema:givenName Ketti
90 rdf:type schema:Person
91 N6a9b79c933704891b8bd3b947978bef9 schema:issueNumber 1
92 rdf:type schema:PublicationIssue
93 N6ce63a0774234e8382992cef6a56f767 rdf:first Nef4af5c7c2484b4daa3dc73b9d3490bb
94 rdf:rest Nd1e9466e25c54893afc3fa46601ce3ea
95 N742e6dc6a67a48b9a231f90b20d43fc3 rdf:first N64aeb8d93bfb48bf89c6d78ef00b0086
96 rdf:rest Nd8acfdb7336a44d389e7040539a4a12b
97 N794d5f5a93a041e98698deec6264467d schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 N7c58565e18a34876a456f344b7256398 rdf:first N5af97cbf56a143e79eba9593911f91f8
100 rdf:rest N742e6dc6a67a48b9a231f90b20d43fc3
101 N83b5d5b0d62c45fe93e8a7609744981c schema:affiliation https://www.grid.ac/institutes/grid.410513.2
102 schema:familyName Wang
103 schema:givenName Lisy
104 rdf:type schema:Person
105 N85dc530cb0644714a73c242fbf1ab549 schema:affiliation N5215375658cf44d98b26b4b809120481
106 schema:familyName Wollenhaupt
107 schema:givenName Jürgen
108 rdf:type schema:Person
109 N8a79e741052e48ac861c923a060f3d56 rdf:first N1fd93f16c5074118bc5e03f7e3f2c9fc
110 rdf:rest Na0bd0181a87648e7a87054557172c882
111 N964d47a47a5d475e90858558458ec653 rdf:first N5290ccccdfc8408a99fc37a1af82567b
112 rdf:rest rdf:nil
113 N9b95fae87d6a4daf901b676cf2e16aab schema:affiliation https://www.grid.ac/institutes/grid.410513.2
114 schema:familyName Soma
115 schema:givenName Koshika
116 rdf:type schema:Person
117 N9be41f31c06e4da3a78d1488c55b7c8f rdf:first Nfb665a6559b54efdbe89f684d16fbc73
118 rdf:rest Naeb8facf4b2a46f1875a28b526531541
119 Na0bd0181a87648e7a87054557172c882 rdf:first N83b5d5b0d62c45fe93e8a7609744981c
120 rdf:rest N964d47a47a5d475e90858558458ec653
121 Na30384eafe964b2886d4e209aa2142b1 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
122 schema:familyName Kwok
123 schema:givenName Kenneth
124 rdf:type schema:Person
125 Na3da75d7105f4d16968b53f197f1a5f3 schema:affiliation https://www.grid.ac/institutes/grid.31501.36
126 schema:familyName Lee
127 schema:givenName Eun-Bong
128 rdf:type schema:Person
129 Naeb8facf4b2a46f1875a28b526531541 rdf:first Na30384eafe964b2886d4e209aa2142b1
130 rdf:rest N8a79e741052e48ac861c923a060f3d56
131 Nb92ea10bd2134c71be6bf5f79fd70bc2 rdf:first N4a8f70030e614f9494960b5c45dfe57b
132 rdf:rest N7c58565e18a34876a456f344b7256398
133 Nc35f82bfa1524ac3ac29a04d459cadb0 schema:name doi
134 schema:value 10.1186/s13075-019-1866-2
135 rdf:type schema:PropertyValue
136 Nc94ae35a0e94431c99d5555ee80fd007 rdf:first Na3da75d7105f4d16968b53f197f1a5f3
137 rdf:rest Nb92ea10bd2134c71be6bf5f79fd70bc2
138 Nd1e9466e25c54893afc3fa46601ce3ea rdf:first Nea6694169d5c4c7c9cef9856ea6c3a7a
139 rdf:rest N9be41f31c06e4da3a78d1488c55b7c8f
140 Nd8acfdb7336a44d389e7040539a4a12b rdf:first N9b95fae87d6a4daf901b676cf2e16aab
141 rdf:rest N6ce63a0774234e8382992cef6a56f767
142 Nea6694169d5c4c7c9cef9856ea6c3a7a schema:affiliation https://www.grid.ac/institutes/grid.410513.2
143 schema:familyName DeMasi
144 schema:givenName Ryan
145 rdf:type schema:Person
146 Necc92a437aca4e05a9e595144fceeafa schema:name Healthpoint Medical Group, Tampa, FL, USA.
147 rdf:type schema:Organization
148 Nef4af5c7c2484b4daa3dc73b9d3490bb schema:affiliation https://www.grid.ac/institutes/grid.410513.2
149 schema:familyName Mojcik
150 schema:givenName Chris
151 rdf:type schema:Person
152 Nf0658dac004e4a9ba2817ae374f52164 schema:name IQVIA Canada, Montréal, Quebec, Canada.
153 rdf:type schema:Organization
154 Nf346b2667d544047b015ef78ed03415e schema:volumeNumber 21
155 rdf:type schema:PublicationVolume
156 Nf53504ca49cb40e69192b069b145d22a schema:name nlm_unique_id
157 schema:value 101154438
158 rdf:type schema:PropertyValue
159 Nfb665a6559b54efdbe89f684d16fbc73 schema:affiliation https://www.grid.ac/institutes/grid.487416.8
160 schema:familyName Strengholt
161 schema:givenName Sander
162 rdf:type schema:Person
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
167 schema:name Clinical Sciences
168 rdf:type schema:DefinedTerm
169 sg:journal.1297499 schema:issn 1478-6354
170 1478-6362
171 schema:name Arthritis Research & Therapy
172 rdf:type schema:Periodical
173 sg:pub.10.1007/s40744-018-0097-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101169712
174 https://doi.org/10.1007/s40744-018-0097-3
175 rdf:type schema:CreativeWork
176 sg:pub.10.1186/s13075-016-0932-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008879334
177 https://doi.org/10.1186/s13075-016-0932-2
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1002/acr.20494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049859067
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1002/acr.22039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031937720
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1002/art.24567 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035997671
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/art.33383 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001564462
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/art.33419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050813312
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/art.37816 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042973954
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1002/art.38687 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012858308
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1002/art.39761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016554784
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1002/art.39972 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006385965
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1002/art.40580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104327999
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1002/art.40780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109891225
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.clinthera.2016.11.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018628442
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s0140-6736(12)61424-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013407721
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s0140-6736(17)31618-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086040585
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1056/nejmoa1109071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010422264
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejmoa1112072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002267298
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa1310476 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024691370
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/eurheartj/ehx145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084183736
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/rheumatology/kev249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060012588
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1136/annrheumdis-2013-204627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038025398
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1136/annrheumdis-2015-207319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006915863
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1136/annrheumdis-2015-209055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034784737
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1136/annrheumdis-2015-209064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041863543
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1136/annrheumdis-2016-210457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083399754
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1136/ard.2005.043166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015096737
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1136/ard.2009.118935 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038366856
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1136/rmdopen-2017-000491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100989117
232 rdf:type schema:CreativeWork
233 https://doi.org/10.3109/14397595.2014.995875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049271633
234 rdf:type schema:CreativeWork
235 https://doi.org/10.3899/jrheum.130683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043063467
236 rdf:type schema:CreativeWork
237 https://doi.org/10.3899/jrheum.170344 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103284630
238 rdf:type schema:CreativeWork
239 https://doi.org/10.7326/0003-4819-159-4-201308200-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073713806
240 rdf:type schema:CreativeWork
241 https://www.grid.ac/institutes/grid.265892.2 schema:alternateName University of Alabama at Birmingham
242 schema:name University of Alabama at Birmingham, Birmingham, AL, USA.
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.267313.2 schema:alternateName The University of Texas Southwestern Medical Center
245 schema:name Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
246 rdf:type schema:Organization
247 https://www.grid.ac/institutes/grid.31501.36 schema:alternateName Seoul National University
248 schema:name Seoul National University, Seoul, Republic of Korea.
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
251 schema:name Pfizer Inc, Collegeville, PA, USA.
252 Pfizer Inc, Groton, CT, USA.
253 Pfizer Inc, Groton, CT, USA. Lisy.Wang@pfizer.com.
254 Pfizer Inc, New York, NY, USA.
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.487416.8 schema:alternateName Pfizer (Netherlands)
257 schema:name Pfizer Inc, Capelle aan den Ijssel, Netherlands.
258 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...